JNJ Q4 2025 sales $24.6B (+9.1% YoY), net earnings $5.1B ($2.10 EPS); adj. EPS $2.46

JOHNSON & JOHNSON

2025-FY EPS reported $11.03 revenue$94,193,000,000

Q4 sales $24,564M (+9.1% YoY); full-year sales $94,193M (+6.0% YoY).
Q4 net earnings $5,116M ($2.10 diluted EPS) vs $3,431M ($1.41) a year ago.
Adjusted Q4 net earnings $6,009M ($2.46 adj. diluted EPS) vs $4,946M ($2.04).
R&D expense decreased 19.7% YoY to $4,252M; effective tax rate was -3.0%.
MedTech segment sales $8,801M (+7.5% YoY); Innovative Medicine $15,763M (+10.0% YoY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.